Sunshine Biopharma, Inc.
SBFM
$1.48
$0.085.71%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.07% | 5.72% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.07% | 5.72% | |||
| Cost of Revenue | 5.95% | -2.97% | |||
| Gross Profit | -10.21% | 25.36% | |||
| SG&A Expenses | -18.93% | 10.96% | |||
| Depreciation & Amortization | 32.14% | 11.88% | |||
| Other Operating Expenses | 6.39% | 2.27% | |||
| Total Operating Expenses | -4.36% | 2.02% | |||
| Operating Income | 46.41% | 23.38% | |||
| Income Before Tax | 48.42% | -62.31% | |||
| Income Tax Expenses | 34.32% | -420.40% | |||
| Earnings from Continuing Operations | 50.09% | -50.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 50.09% | -50.09% | |||
| EBIT | 46.41% | 23.38% | |||
| EBITDA | 52.65% | 25.24% | |||
| EPS Basic | 50.75% | 9.74% | |||
| Normalized Basic EPS | 50.94% | 54.75% | |||
| EPS Diluted | 50.75% | 9.74% | |||
| Normalized Diluted EPS | 50.94% | 54.75% | |||
| Average Basic Shares Outstanding | 1.33% | 66.32% | |||
| Average Diluted Shares Outstanding | 1.33% | 66.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||